Stocks and Investing Stocks and Investing
Thu, March 7, 2024
Wed, March 6, 2024

Rachel Vatnsdal Maintained (AKYA) at Buy with Decreased Target to $10 on, Mar 6th, 2024


Published on 2024-10-28 09:30:34 - WOPRAI, Rachel Vatnsdal
  Print publication without navigation


Rachel Vatnsdal of JP Morgan, Maintained "Akoya Biosciences, Inc." (AKYA) at Buy with Decreased Target from $12 to $10 on, Mar 6th, 2024.

Rachel has made no other calls on AKYA in the last 4 months.



There are 5 other peers that have a rating on AKYA. Out of the 5 peers that are also analyzing AKYA, 1 agrees with Rachel's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Subbu Nambi of "Guggenheim" Initiated at Hold on, Thursday, December 14th, 2023


These are the ratings of the 4 analyists that currently disagree with Rachel


  • John Sourbeer of "UBS" Maintained at Strong Buy with Increased Target to $7.5 on, Tuesday, March 5th, 2024
  • Kyle Mikson of "Canaccord Genuity" Reiterated at Strong Buy and Held Target at $10 on, Tuesday, March 5th, 2024
  • David Westenberg of "Piper Sandler" Maintained at Buy with Decreased Target to $8 on, Monday, November 13th, 2023
  • Mason Carrico of "Stephens & Co." Maintained at Buy with Decreased Target to $9 on, Monday, November 13th, 2023
Contributing Sources